Evidence map›Paper›PMID 38603576›Full record

ArticleThe Journal of urology2024

Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health-Related Quality of Life Measures: An Assessment of the Comparative Effectiveness and Survivorship Health in Bladder Cancer (CEASE-BC) Study.

Hannah Kay, Sarah N Silver, Angela B Smith, Ramsankar Basak, Kimberly Shoenbill, Deborah Usinger, Adam O Goldstein, Richard S Matulewicz, Ronald Chen, Marc A Bjurlin

Open access · greenAbstract read
In one paragraph

Article in The Journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Diagnostic predictive models for cancer-related fatigue: current evidence and future directions.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Hannah KayDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Sarah N SilverDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Angela B SmithDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Ramsankar BasakDepartment of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Kimberly ShoenbillLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Deborah UsingerDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Adam O GoldsteinLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Richard S MatulewiczDepartment of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Ronald ChenDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas.
Marc A BjurlinDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-3500-8849
University of North Carolina at Chapel Hill · USMemorial Sloan Kettering Cancer Center · USUniversity of Kansas Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Optimizing Smoking Cessation Treatment for Patients with Bladder CancerK08CA259452 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Richard Steven Matulewicz · 2022 to 2026
$971k
NCI NIH HHS K08 CA259452NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016086
6 · The paper itself

Abstract

purposeCigarette smoking is the most common risk factor for the development of bladder cancer (BC), yet there is a paucity of data characterizing the relationship between smoking status and longitudinal health-related quality of life (HRQoL) outcomes in patients with BC. We examined the association between smoking status and HRQoL among patients with BC. MATERIALS AND

methodsData were sourced from a prospective, longitudinal study open between 2014 and 2017, which examined HRQoL in patients aged ≥ 18 years old diagnosed with BC across North Carolina. The QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core instrument) was administered at 3, 12, and 24 months after BC diagnosis. Our primary exposure of interest was current smoking status. Linear regression using generalized estimating equations was used to analyze the relationship between smoking status and various domains of the QLQ-C30.

resultsA total of 154 patients enrolled in the study. Eighteen percent were classified as smoking at 3 months from diagnosis, and packs per day ranged from < 0.5 to 2. When controlling for time from diagnosis, demographic covariates, cancer stage, and treatment type, mean differences for physical function (7.4), emotional function (5.6), and fatigue measures (-8.2) were significantly better for patients with BC who did not smoke.

conclusionsPatients with BC who do not smoke have significantly better HRQoL scores in the domains of physical function, emotional function, and fatigue. These results underscore the need to treat smoking as an essential component of BC care.

Indexed as

Cancer SurvivorsQuality of LifeUrinary Bladder NeoplasmsAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedNon-SmokersProspective StudiesSmokingSurveys and Questionnairesbladder cancerquality of lifesmokingtobacco

Identifiers

PMID38603576
PMCPMC11193885
OpenAlexW4394728532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.